Johnson & Johnson (NYSE:JNJ) Guggenheim Global Healthcare Conference November 12, 2024 10:30 AM ET Company Participants Biljana Naumovic - Worldwide VP, Global Commercial Strategy, Oncology Mark Wildgust - VP, Global Medical Affairs Oncology Conference Call Participants Vamil Divan - Guggenheim Securities Edouard Mullarky - Guggenheim Securities Vamil Divan All right. I think we're ready to get started. Thanks, everyone, again, for joining us at the Guggenheim Inaugural Healthcare Innovation Conference this ...

Group 1 - Johnson & Johnson is participating in the Guggenheim Global Healthcare Conference, focusing on oncology advancements [1][2] - The discussion will primarily cover three main areas: lung cancer, bladder cancer, and multiple myeloma [3] - There is a perceived disconnect between Johnson & Johnson's view of opportunities in lung cancer and the market's current perception [3] Group 2 - The company is making significant progress in bladder cancer treatments, which will also be addressed during the conference [3] - Johnson & Johnson holds a dominant position in the myeloma treatment space and is taking steps to enhance its offerings [3]

Readers who have been with me for a while may know how hard it is for me to sell stocks. That is based on the fact that I hold a relatively small number of individual companies. Currently, I holdAnalyst’s Disclosure: I/we have a beneficial long position in the shares of EXR, REXR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship w ...

It has been about a month since the last earnings report for Johnson & Johnson (JNJ) . Shares have lost about 6.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Johnson & Johnson due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q3 Earnings & Sales Top, Sales V ...

Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease based on results from the Phase 2 DAHLIAS studyWASHINGTON, Nov. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today an ...

With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Re ...

The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the Phase 2 DAHLIAS studyA greater than 70 percent relative improvement in systemic disease activity at Week 24 was demonstrated in study participants on average who received nipocalimab 15 mg/kg compared to participants who received placeboNipocalimab was granted BTD in hemolytic disease of the fetus and newborn e ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.Start slideshow: 10 Oversold Stocks You Should Know About »In trading on Monday, shares of Johnson & Johnson entered int ...

If approved, daratumumab will become the first treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active disease and the occurrence of end organ damage1 BEERSE, BELGIUM, Nov. 08, 2024 (GLOBE NEWSWIRE) --  Janssen-Cilag International NV, a Johnson & Johnson company, today announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agenc ...

If approved, DARZALEX FASPRO® will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset of active disease and the occurrence of end organ damage RARITAN, N.J., Nov. 8, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of a new ind ...